Suba Krishnan, an oncology expert, is to join Mereo BioPharma Group Plc on 7 December as head of clinical development where she will help advance etigilimab, a prospective treatment for advanced solid tumours. Dr Krishnan joins from Genmab A/S where she was global head of immuno-oncology. Prior to this, she was the clinical lead for Merck & Co Inc’s basket study of Lynparza and also held clinical leadership roles at MedImmune and Bristol Myers Squibb Co. At BMS, she had oversight of multiple trials for nivolumab, including a registration study in metastatic bladder cancer.
Mereo BioPharma Group announced the appointment on 23 November 2020.
Copyright 2020 Evernow Publishing Ltd